MD4763C1 - Фармацевтическая композиция - Google Patents
Фармацевтическая композиция Download PDFInfo
- Publication number
- MD4763C1 MD4763C1 MDA20180049A MD20180049A MD4763C1 MD 4763 C1 MD4763 C1 MD 4763C1 MD A20180049 A MDA20180049 A MD A20180049A MD 20180049 A MD20180049 A MD 20180049A MD 4763 C1 MD4763 C1 MD 4763C1
- Authority
- MD
- Moldova
- Prior art keywords
- pharmaceutical composition
- levocarnitine
- arginine
- preparation
- present
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 92
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 82
- 229960001518 levocarnitine Drugs 0.000 claims abstract description 80
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 229960003589 arginine hydrochloride Drugs 0.000 claims abstract description 25
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000008215 water for injection Substances 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 33
- 206010002383 Angina Pectoris Diseases 0.000 claims description 17
- 206010061216 Infarction Diseases 0.000 claims description 3
- 230000002269 spontaneous effect Effects 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 description 114
- 230000004526 pharmaceutical effect Effects 0.000 description 89
- 239000004475 Arginine Substances 0.000 description 60
- 229960003121 arginine Drugs 0.000 description 60
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 60
- 241001465754 Metazoa Species 0.000 description 43
- 230000009467 reduction Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 210000004413 cardiac myocyte Anatomy 0.000 description 26
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 24
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 23
- 210000004165 myocardium Anatomy 0.000 description 23
- 238000000034 method Methods 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 15
- 230000009471 action Effects 0.000 description 11
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 9
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 201000011244 Acrocallosal syndrome Diseases 0.000 description 7
- 102000016938 Catalase Human genes 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 208000019905 acrocephalosyndactyly Diseases 0.000 description 7
- 206010051895 acute chest syndrome Diseases 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108010053835 Catalase Proteins 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- 206010000891 acute myocardial infarction Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000003293 cardioprotective effect Effects 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940049920 malate Drugs 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010058144 Postinfarction angina Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010002388 Angina unstable Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 102000004903 Troponin Human genes 0.000 description 3
- 108090001027 Troponin Proteins 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001066 destructive effect Effects 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 206010047302 ventricular tachycardia Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000005228 Pericardial Effusion Diseases 0.000 description 2
- 206010034476 Pericardial haemorrhage Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 201000002303 hemopericardium Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010007513 Cardiac aneurysm Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000004196 Heart Aneurysm Diseases 0.000 description 1
- 208000000435 Heart Rupture Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101100173048 Mus musculus Mcat gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010033698 Papillary muscle rupture Diseases 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043248 Tendon rupture Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001171 adenosinetriphosphoric effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004971 interatrial septum Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 230000018341 negative regulation of fibrinolysis Effects 0.000 description 1
- 230000019261 negative regulation of glycolysis Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относится к медицине, а именно к средствам для лечения ишемической болезни сердца и ее последствий. Фармацевтическая композиция содержит аргинина гидрохлорид, левокарнитин и воду для инъекций.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201511330U UA106905U (ru) | 2015-11-17 | 2015-11-17 | Фармацевтическая композиция |
| UAA201611435A UA119768C2 (uk) | 2016-11-11 | 2016-11-11 | Фармацевтична композиція |
| PCT/IB2016/056901 WO2017085642A1 (ru) | 2015-11-17 | 2016-11-16 | Фармацевтическая композиция |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20180049A2 MD20180049A2 (ru) | 2018-09-30 |
| MD4763B1 MD4763B1 (ru) | 2021-08-31 |
| MD4763C1 true MD4763C1 (ru) | 2022-03-31 |
Family
ID=58718454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20180049A MD4763C1 (ru) | 2015-11-17 | 2016-11-16 | Фармацевтическая композиция |
Country Status (2)
| Country | Link |
|---|---|
| MD (1) | MD4763C1 (ru) |
| WO (1) | WO2017085642A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022018705A1 (en) * | 2020-07-24 | 2022-01-27 | M.T.K. Medical Center Limited Liability Company | A pharmaceutical composition for treating cardiovascular and cerebrovascular disorders,diseases in pregnant women and improving exercise tolerance |
| WO2022018707A1 (en) * | 2020-07-24 | 2022-01-27 | M.T.K. Medical Center Limited Liability Company | Infusion solution comprising arginine hydrochloride and levocarnitine for treatment and prevention of diseases in pregnant women and promotion of fetal development during pregnancy |
| UA126094C2 (uk) * | 2020-07-24 | 2022-08-10 | Тов "Медичний Центр "М.Т.К." | Застосування розчину для інфузій для лікування захворювань, пов'язаних із порушеннями мозкового кровообігу |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101336914B (zh) * | 2007-07-03 | 2011-12-28 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种缩小心肌梗死面积的药物组合物及其应用 |
| CN103948581B (zh) * | 2014-02-26 | 2018-05-08 | 青岛大学医学院附属医院 | 左卡尼汀联合l-精氨酸在制备治疗糖尿病视网膜病变神经损伤药物中的应用 |
-
2016
- 2016-11-16 WO PCT/IB2016/056901 patent/WO2017085642A1/ru not_active Ceased
- 2016-11-16 MD MDA20180049A patent/MD4763C1/ru active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017085642A1 (ru) | 2017-05-26 |
| MD4763B1 (ru) | 2021-08-31 |
| MD20180049A2 (ru) | 2018-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7179888B2 (ja) | 心臓肥大および肺高血圧の治療用医薬の製造におけるカウラン化合物の使用 | |
| Guimarães et al. | Exercise induces renin–angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice | |
| JP2011518785A (ja) | 心血管入院または死亡の予防に用いる薬剤を調製するためのドロネダロンの使用 | |
| CN105727269B (zh) | 神经氨酸酶及其抑制剂在心肌缺血及心肌梗死中的应用 | |
| Dadson et al. | Cellular, structural and functional cardiac remodelling following pressure overload and unloading | |
| Deng et al. | Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia | |
| Singhal et al. | Colchicine suppresses atrial fibrillation in failing heart | |
| SG181541A1 (en) | Method of treating atrial fibrillation | |
| CN105748464A (zh) | 一种治疗射血分数保留的心力衰竭的药物组合物及其应用 | |
| Mouton et al. | Exposure to chronic alcohol accelerates development of wall stress and eccentric remodeling in rats with volume overload | |
| Jiao et al. | Effects of valsartan on ventricular arrhythmia induced by programmed electrical stimulation in rats with myocardial infarction | |
| Choudhury et al. | Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy? | |
| Di Pasquale et al. | Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction | |
| WO2017085642A1 (ru) | Фармацевтическая композиция | |
| CN105168233A (zh) | 20(S)-人参皂苷Rg3作为SIRT1蛋白激动剂的用途 | |
| CN114344296A (zh) | Nat10抑制剂在诊治压力超负荷所致心力衰竭中的应用 | |
| CN108143735A (zh) | 毛壳素在制备预防和治疗低氧性肺动脉高压药物中的应用 | |
| Chang et al. | Protein kinases are involved in the cardioprotective effects activated by platelet glycoprotein IIb/IIIa inhibitor tirofiban at reperfusion in rats in vivo | |
| Gao et al. | Beneficial effects of houttuynin on ventricular remodeling induced by coronary artery ligation in rats | |
| Coppolino et al. | Endothelial progenitor cells at the interface of chronic kidney disease: from biology to therapeutic advancement | |
| Wu et al. | Loss of anti-arrhythmic effect of vagal nerve stimulation on ischemia-induced ventricular tachyarrhythmia in aged rats | |
| Yu et al. | Cytidine diphosphate choline improves the outcome of cardiac arrest vs epinephrine in rat model | |
| Ay et al. | Effects of ischemic preconditioning and iloprost on myocardial ischemia-reperfusion damage in rats | |
| Yamakawa et al. | Improved cardioprotection using a novel stepwise ischemic preconditioning protocol in rabbit heart | |
| CN117257803A (zh) | 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued |